Exicure, inc. (nasdaq: xcur) nears completion of phase 2 study of gpc-100 in multiple myeloma

Redwood city, calif.--(business wire)--exicure, inc. nears completion of phase 2 study of gpc-100 in multiple myeloma.
XCUR Ratings Summary
XCUR Quant Ranking